17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
Inventors
Wang, Guoqiang • Ma, Jun • Granger, Brett • Long, Jiang • Wang, Bin • Ghorai, Sourav • He, Jing • He, Yong • Xing, Xuechao • Shen, Ruichao • Or, Yat Sun
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.
Core Innovation
The disclosed subject matter provides compounds represented by Formulas (X-2), (X-3), (X-4), (X-5), (X-6), (X-11), and (X-12), Formula (I), or pharmaceutically acceptable salts thereof as 17̲-HSD13 inhibitors. The chemical scaffold encompasses sulfonyl-linked arrangements of variable aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and cycloalkenyl groups. These structures include substituted thiazole-sulfonamides and methoxy-substituted carboxyphenyl moieties with defined linkers and variable terminal substituents.
The compounds inhibit HSD17B13 in mass spectrometry screening results measuring the conversion of leukotriene B4 to 12-oxo-leukotriene B4. Reported IC50 values range from less than 0.1 ̲M to greater than 100 ̲M, with multiple analogs demonstrating values below 0.5 ̲M. Disclosed embodiments encompass pharmaceutical compositions for modulating HSD17B13 and treating or preventing metabolic or liver conditions, including alcoholic and non-alcoholic liver disease.
Claims Coverage
The claims identify one independent claim directed to formula-defined compounds and their pharmaceutically acceptable salts, presenting two inventive features.
Formula-defined compounds and pharmaceutically acceptable salts
Claim 1 covers a compound represented by one of Formulas (X-2), (X-3), (X-4), (X-5), (X-6), (X-11), and (X-12), or a pharmaceutically acceptable salt thereof, with defined alternatives for substituents R11, R12, and R13, integers n and m, an optionally substituted aryl group, and optionally substituted cycloalkyl, heterocycloalkyl, or cycloalkenyl groups.
Pharmaceutical composition
A claim element in the dependent claims covers a pharmaceutical composition comprising a claim 1 compound or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
The claims cover the specified formula-defined compounds, their substituent variants, and pharmaceutically acceptable salts, as well as pharmaceutical compositions containing them.
Stated Advantages
The reported examples show HSD17B13 inhibitory activity, including multiple compounds with IC50 values below 0.5 ̲M.
Documented Applications
A pharmaceutical composition comprising a claimed compound or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
Modulation of HSD17B13 and treatment or prevention of metabolic or liver conditions, including alcoholic and non-alcoholic liver disease.
Evaluation of compounds for HSD17B13 inhibition using an assay measuring leukotriene B4 conversion to 12-oxo-leukotriene B4.
Interested in licensing this patent?